Abstract
BackgroundWith its high morbidity and mortality, acute myocardial infarction (AMI) places a major burden on society and on individual patients. Correct, early correct diagnosis is crucial to the management of AMI.MethodsIn this study, the expression of circulating miR-486 and miR-150 was investigated in AMI patients and the two miRNAs were evaluated as potential biomarkers for AMI. Plasma samples from 110 patients with AMI (65 patients with ST-segment elevation myocardial infarction (STEMI) and 45 patients with non-ST-segment elevation myocardial infarction (NSTEMI)) and 110 healthy adults were collected. Circulating levels of miR-486 and miR-150 were detected using quantitative real-time PCR in plasma samples.ResultsResults showed that the levels of miR-486 and miR-150 were significantly higher in AMI patients than in healthy controls. Receiver operating characteristic (ROC) curve analyses indicated that the two plasma miRNAs were of significant diagnostic value for AMI, especially NSTEMI. The combined ROC analysis revealed an AUC value of 0.771 in discriminating AMI patients from healthy controls and an AUC value of 0.845 in discriminating NSTEMI patients from healthy controls.ConclusionResults indicated that the levels of circulating miR-486 and miR-150 are associated with AMI. They may be novel and powerful biomarkers for AMI, especially for NSTEMI.
Highlights
With its high morbidity and mortality, acute myocardial infarction (AMI) places a major burden on society and on individual patients
AMI is separated into two categories based on changes seen in the electrocardiography (ECG): ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI)
We performed a preliminary plasma miRNA microassay chip analysis of AMI patients and healthy controls and the results showed significant changes in the levels of miR-486 and miR-150 in AMI patients which was in accordance with a recent study about serum miR-486 and miR-150 [28]
Summary
With its high morbidity and mortality, acute myocardial infarction (AMI) places a major burden on society and on individual patients. AMI is one of the most frequently occurring cardiovascular diseases and one of the leading causes of morbidity and mortality in both developed and developing countries [2,3,4]. With China’s aging population and the projected increase in the rate of this disease, it is estimated that 16 million people will suffer from AMI in 2020 and 23 million in 2030 [5]. Because it is the world’s largest developing country, China is challenged to provide care for its large and growing population of AMI patients [6]. In STEMI, the infarct-related artery is usually totally occluded by fibrin-
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
